# Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

> **NCT07441395** · PHASE2 · RECRUITING · sponsor: **Corvus Pharmaceuticals, Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Atopic Dermatitis
- Atopic Dermatitis Eczema
- Eczema
- Eczema, Atopic

## Interventions

- **DRUG:** Soquelitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07441395
- **Lead sponsor:** Corvus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-06
- **Final completion:** 2027-09
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07441395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07441395, "Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07441395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*